Dr. Agarwal's IPO Funds Used As Planned, ICRA Confirms No Deviation

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Dr. Agarwal's IPO Funds Used As Planned, ICRA Confirms No Deviation
Overview

ICRA Limited has confirmed that Dr. Agarwal's Health Care Limited has utilized its Initial Public Offer (IPO) proceeds strictly in line with the objects disclosed in its offer document for the quarter ended December 31, 2025. The report highlights that ₹269.38 Crore has been utilized, with ₹30.62 Crore remaining unutilized and placed in fixed deposits. No deviation from the IPO's stated objectives was observed.

📊 IPO Proceeds Utilization Analysis

ICRA Limited's monitoring report, issued on February 02, 2026, for Dr. Agarwal's Health Care Limited, provides a crucial update on the utilization of funds raised through its Initial Public Offer (IPO).

The Core Finding: No Deviation
The central finding of the report is the confirmation that there has been no deviation from the stated objects of the issue concerning the utilization of IPO proceeds. This indicates strong adherence to the disclosures made in the company's offer document and reinforces its commitment to financial transparency and governance.

Key Financials of IPO Proceeds Utilization

  • Gross Proceeds Monitored: ICRA monitored gross proceeds of ₹300.00 Crore for the quarter ended December 31, 2025.
  • Total Utilized (Net Proceeds): As of December 31, 2025, a cumulative amount of ₹269.38 Crore has been utilized from the net proceeds.
  • Total Unutilized Amount: The remaining unutilized amount stands at ₹30.62 Crore.

Fund Allocation & Usage Breakdown
The report details the deployment of funds against the allocated objectives:

  1. Repayment/prepayment of certain borrowings:

    • Allocated: ₹195.00 Crore
    • Utilized: ₹195.00 Crore (100% utilized).

  2. General corporate purposes:

    • Allocated: ₹77.47 Crore
    • Utilized: ₹61.91 Crore by quarter-end.
    • Unutilized under this head: ₹15.56 Crore.
    • Specific expenditures include: Purchase of medical equipment & consumables (**₹22.78 Crore*), electrical and office equipment (₹2.88 Crore), projects (Interior works) (₹12.19 Crore), consideration for Non-compete Agreement (₹0.81 Crore), deferred payment for acquisitions (₹23.11 Crore), and security deposit for office premises (₹0.14 Crore).

  3. Issue related expenses:

    • Allocated: ₹27.53 Crore
    • Utilized: ₹12.48 Crore.
    • Unutilized under this head: ₹15.05 Crore.

Deployment of Unutilized Proceeds
The total unutilized funds of ₹30.62 Crore as at the end of the quarter, along with an additional ₹9.975 Crore (interest earned on fixed deposits and portion of OFS proceeds), are placed in fixed deposits with reputed banks and financial institutions. These include investments in Axis Bank, Yes Bank, Union Bank, and Bajaj Finance Limited, with varying maturity dates and interest rates.

Implementation Status & Investor Confidence
The report confirms that the objects of the issue, including repayment of borrowings and general corporate purposes, are on schedule, with no delays noted. This meticulous tracking and reporting by ICRA, validated by company management confirmations, significantly bolsters investor confidence. It highlights Dr. Agarwal's Health Care's commitment to financial integrity and transparent execution of its strategic plans outlined during the IPO, a critical factor for maintaining stakeholder trust and potentially influencing future investment decisions.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.